Annual EBITDA:
$656.54M+$204.59M(+45.27%)Summary
- As of today, HALO annual EBITDA is $656.54 million, with the most recent change of +$204.59 million (+45.27%) on December 31, 2024.
- During the last 3 years, HALO annual EBITDA has risen by +$397.50 million (+153.45%).
- HALO annual EBITDA is now at all-time high.
Performance
HALO EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Quarterly EBITDA:
$238.38M+$15.48M(+6.94%)Summary
- As of today, HALO quarterly EBITDA is $238.38 million, with the most recent change of +$15.48 million (+6.94%) on September 30, 2025.
- Over the past year, HALO quarterly EBITDA has increased by +$54.82 million (+29.87%).
- HALO quarterly EBITDA is now at all-time high.
Performance
HALO Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
TTM EBITDA:
$819.19M+$54.82M(+7.17%)Summary
- As of today, HALO TTM EBITDA is $819.19 million, with the most recent change of +$54.82 million (+7.17%) on September 30, 2025.
- Over the past year, HALO TTM EBITDA has increased by +$260.55 million (+46.64%).
- HALO TTM EBITDA is now at all-time high.
Performance
HALO TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
HALO EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1Y1 Year | +45.3% | +29.9% | +46.6% |
| 3Y3 Years | +153.4% | +111.2% | +162.7% |
| 5Y5 Years | +1260.9% | +480.0% | +1086.8% |
HALO EBITDA Highs & Lows
| PeriodPeriod | Annual vs HighAnnual vs High | Annual vs LowAnnual vs Low | Quarter. vs HighQuarter. vs High | Quarter. vs LowQuarter. vs Low | TTM vs HighTTM vs High | TTM vs LowTTM vs Low | |
|---|---|---|---|---|---|---|---|
| 3Y | 3-Year | at high | +153.4% | at high | +221.0% | at high | +162.7% |
| 5Y | 5-Year | at high | +1260.9% | at high | +480.0% | at high | +1086.8% |
| All-Time | All-Time | at high | +926.1% | at high | +985.4% | at high | +954.9% |
HALO EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2025 | - | $238.38M(+6.9%) | $819.19M(+7.2%) |
| Jun 2025 | - | $222.90M(+37.6%) | $764.36M(+12.6%) |
| Mar 2025 | - | $161.98M(-17.3%) | $679.06M(+7.3%) |
| Dec 2024 | $656.54M(+45.3%) | $195.92M(+6.7%) | $632.82M(+13.3%) |
| Sep 2024 | - | $183.56M(+33.4%) | $558.63M(+14.9%) |
| Jun 2024 | - | $137.60M(+18.9%) | $486.39M(+4.9%) |
| Mar 2024 | - | $115.75M(-4.9%) | $463.89M(+9.8%) |
| Dec 2023 | $451.95M(+43.2%) | $121.73M(+9.3%) | $422.40M(+10.1%) |
| Sep 2023 | - | $111.32M(-3.3%) | $383.69M(-0.4%) |
| Jun 2023 | - | $115.09M(+55.0%) | $385.26M(+14.9%) |
| Mar 2023 | - | $74.26M(-10.6%) | $335.33M(-0.6%) |
| Dec 2022 | $315.51M(+21.8%) | $83.02M(-26.5%) | $337.52M(+8.2%) |
| Sep 2022 | - | $112.89M(+73.2%) | $311.80M(+13.3%) |
| Jun 2022 | - | $65.16M(-14.8%) | $275.20M(-9.4%) |
| Mar 2022 | - | $76.45M(+33.4%) | $303.89M(+9.0%) |
| Dec 2021 | $259.04M(+69.3%) | $57.31M(-24.9%) | $278.91M(-7.0%) |
| Sep 2021 | - | $76.29M(-18.7%) | $300.03M(+13.3%) |
| Jun 2021 | - | $93.85M(+82.3%) | $264.84M(+31.5%) |
| Mar 2021 | - | $51.47M(-34.4%) | $201.35M(+36.5%) |
| Dec 2020 | $152.96M(+370.5%) | $78.42M(+90.8%) | $147.51M(+113.7%) |
| Sep 2020 | - | $41.10M(+35.4%) | $69.03M(+1472.0%) |
| Jun 2020 | - | $30.36M(+1383.0%) | $4.39M(+111.3%) |
| Mar 2020 | - | -$2.37M(-3778.7%) | -$38.94M(-19.4%) |
| Dec 2019 | -$56.56M(+4.7%) | -$61.00K(+99.7%) | -$32.62M(-1.8%) |
| Sep 2019 | - | -$23.54M(-81.4%) | -$32.04M(+4.0%) |
| Jun 2019 | - | -$12.98M(-428.0%) | -$33.38M(+16.3%) |
| Mar 2019 | - | $3.96M(+662.2%) | -$39.87M(+40.5%) |
| Dec 2018 | -$59.36M(-169.2%) | $519.00K(+102.1%) | -$66.97M(-213.7%) |
| Sep 2018 | - | -$24.87M(-27.7%) | $58.93M(-36.2%) |
| Jun 2018 | - | -$19.47M(+15.9%) | $92.38M(+6.2%) |
| Mar 2018 | - | -$23.15M(-118.3%) | $86.97M(+4.5%) |
| Dec 2017 | $85.75M(+207.9%) | $126.42M(+1374.0%) | $83.20M(+227.7%) |
| Sep 2017 | - | $8.58M(+134.5%) | -$65.16M(+32.0%) |
| Jun 2017 | - | -$24.88M(+7.6%) | -$95.82M(-4.1%) |
| Mar 2017 | - | -$26.92M(-22.8%) | -$92.04M(-13.9%) |
| Dec 2016 | -$79.47M(-213.5%) | -$21.93M(+0.7%) | -$80.80M(-52.6%) |
| Sep 2016 | - | -$22.09M(-4.7%) | -$52.95M(+1.4%) |
| Jun 2016 | - | -$21.10M(-34.6%) | -$53.69M(-92.0%) |
| Mar 2016 | - | -$15.68M(-364.7%) | -$27.96M(-8.5%) |
| Dec 2015 | -$25.35M(+58.5%) | $5.92M(+125.9%) | -$25.77M(+26.6%) |
| Sep 2015 | - | -$22.84M(-593.6%) | -$35.09M(-13.9%) |
| Jun 2015 | - | $4.63M(+134.3%) | -$30.82M(+38.3%) |
| Mar 2015 | - | -$13.49M(-297.6%) | -$49.94M(+18.5%) |
| Dec 2014 | -$61.03M(+22.7%) | -$3.39M(+81.7%) | -$61.27M(+22.3%) |
| Sep 2014 | - | -$18.56M(-28.0%) | -$78.87M(-0.5%) |
| Jun 2014 | - | -$14.50M(+41.6%) | -$78.50M(+8.5%) |
| Mar 2014 | - | -$24.82M(-18.3%) | -$85.83M(-8.4%) |
| Dec 2013 | -$78.98M | -$20.99M(-15.4%) | -$79.21M(-27.1%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2013 | - | -$18.19M(+16.6%) | -$62.34M(+2.4%) |
| Jun 2013 | - | -$21.82M(-19.9%) | -$63.89M(-14.4%) |
| Mar 2013 | - | -$18.20M(-341.4%) | -$55.84M(-6.3%) |
| Dec 2012 | -$52.47M(-181.0%) | -$4.12M(+79.1%) | -$52.55M(+21.1%) |
| Sep 2012 | - | -$19.74M(-43.3%) | -$66.61M(-60.6%) |
| Jun 2012 | - | -$13.78M(+7.6%) | -$41.47M(-70.6%) |
| Mar 2012 | - | -$14.90M(+18.0%) | -$24.31M(-29.7%) |
| Dec 2011 | -$18.67M(+64.6%) | -$18.18M(-437.3%) | -$18.74M(-17.3%) |
| Sep 2011 | - | $5.39M(+59.4%) | -$15.98M(+52.2%) |
| Jun 2011 | - | $3.38M(+136.2%) | -$33.44M(+31.2%) |
| Mar 2011 | - | -$9.33M(+39.5%) | -$48.58M(+4.0%) |
| Dec 2010 | -$52.75M(+7.5%) | -$15.42M(-27.8%) | -$50.63M(-6.6%) |
| Sep 2010 | - | -$12.07M(-2.6%) | -$47.49M(+3.1%) |
| Jun 2010 | - | -$11.76M(-3.4%) | -$48.99M(+9.2%) |
| Mar 2010 | - | -$11.38M(+7.4%) | -$53.96M(+5.4%) |
| Dec 2009 | -$57.01M(-15.4%) | -$12.28M(+9.5%) | -$57.01M(+7.2%) |
| Sep 2009 | - | -$13.57M(+18.9%) | -$61.47M(-4.5%) |
| Jun 2009 | - | -$16.73M(-16.0%) | -$58.82M(-10.5%) |
| Mar 2009 | - | -$14.43M(+13.8%) | -$53.21M(-7.7%) |
| Dec 2008 | -$49.39M(-79.1%) | -$16.74M(-53.3%) | -$49.39M(-16.6%) |
| Sep 2008 | - | -$10.92M(+1.9%) | -$42.36M(-7.0%) |
| Jun 2008 | - | -$11.13M(-4.9%) | -$39.60M(-15.8%) |
| Mar 2008 | - | -$10.61M(-9.2%) | -$34.19M(-24.0%) |
| Dec 2007 | -$27.57M(-79.8%) | -$9.71M(-19.1%) | -$27.57M(-22.8%) |
| Sep 2007 | - | -$8.16M(-42.9%) | -$22.46M(-24.3%) |
| Jun 2007 | - | -$5.71M(-43.0%) | -$18.06M(-15.0%) |
| Mar 2007 | - | -$3.99M(+13.1%) | -$15.71M(-2.4%) |
| Dec 2006 | -$15.34M(-14.9%) | -$4.60M(-22.2%) | -$15.34M(-7.5%) |
| Sep 2006 | - | -$3.76M(-12.1%) | -$14.27M(-0.3%) |
| Jun 2006 | - | -$3.36M(+7.2%) | -$14.23M(-3.4%) |
| Mar 2006 | - | -$3.62M(-2.6%) | -$13.75M(-3.0%) |
| Dec 2005 | -$13.36M(-49.0%) | -$3.53M(+5.2%) | -$13.36M(-8.4%) |
| Sep 2005 | - | -$3.72M(-29.0%) | -$12.32M(-4.2%) |
| Jun 2005 | - | -$2.88M(+10.4%) | -$11.82M(-7.5%) |
| Mar 2005 | - | -$3.22M(-29.4%) | -$11.00M(-22.7%) |
| Dec 2004 | -$8.96M(>-9900.0%) | -$2.49M(+23.0%) | -$8.96M(-37.3%) |
| Sep 2004 | - | -$3.23M(-56.9%) | -$6.53M(-97.3%) |
| Jun 2004 | - | -$2.06M(-73.6%) | -$3.31M(-163.7%) |
| Mar 2004 | - | -$1.19M(-2068.2%) | -$1.25M(-1506.9%) |
| Dec 2003 | $0.00(0.0%) | -$54.70K(-475.8%) | -$78.10K(-76.3%) |
| Sep 2003 | - | -$9500.00(-97.9%) | -$44.30K(+6.5%) |
| Jun 2003 | - | -$4800.00(+47.3%) | -$47.40K(+22.2%) |
| Mar 2003 | - | -$9100.00(+56.5%) | -$60.90K(-54.6%) |
| Dec 2002 | $0.00(+100.0%) | -$20.90K(-65.9%) | -$39.40K(-113.0%) |
| Sep 2002 | - | -$12.60K(+31.1%) | -$18.50K(-213.6%) |
| Jun 2002 | - | -$18.30K(-247.6%) | -$5900.00(-147.6%) |
| Mar 2002 | - | $12.40K | $12.40K |
| Dec 2001 | -$39.70K | - | - |
FAQ
- What is Halozyme Therapeutics, Inc. annual EBITDA?
- What is the all-time high annual EBITDA for Halozyme Therapeutics, Inc.?
- What is Halozyme Therapeutics, Inc. annual EBITDA year-on-year change?
- What is Halozyme Therapeutics, Inc. quarterly EBITDA?
- What is the all-time high quarterly EBITDA for Halozyme Therapeutics, Inc.?
- What is Halozyme Therapeutics, Inc. quarterly EBITDA year-on-year change?
- What is Halozyme Therapeutics, Inc. TTM EBITDA?
- What is the all-time high TTM EBITDA for Halozyme Therapeutics, Inc.?
- What is Halozyme Therapeutics, Inc. TTM EBITDA year-on-year change?
What is Halozyme Therapeutics, Inc. annual EBITDA?
The current annual EBITDA of HALO is $656.54M
What is the all-time high annual EBITDA for Halozyme Therapeutics, Inc.?
Halozyme Therapeutics, Inc. all-time high annual EBITDA is $656.54M
What is Halozyme Therapeutics, Inc. annual EBITDA year-on-year change?
Over the past year, HALO annual EBITDA has changed by +$204.59M (+45.27%)
What is Halozyme Therapeutics, Inc. quarterly EBITDA?
The current quarterly EBITDA of HALO is $238.38M
What is the all-time high quarterly EBITDA for Halozyme Therapeutics, Inc.?
Halozyme Therapeutics, Inc. all-time high quarterly EBITDA is $238.38M
What is Halozyme Therapeutics, Inc. quarterly EBITDA year-on-year change?
Over the past year, HALO quarterly EBITDA has changed by +$54.82M (+29.87%)
What is Halozyme Therapeutics, Inc. TTM EBITDA?
The current TTM EBITDA of HALO is $819.19M
What is the all-time high TTM EBITDA for Halozyme Therapeutics, Inc.?
Halozyme Therapeutics, Inc. all-time high TTM EBITDA is $819.19M
What is Halozyme Therapeutics, Inc. TTM EBITDA year-on-year change?
Over the past year, HALO TTM EBITDA has changed by +$260.55M (+46.64%)